Ahmed ElNawawi (“Nawawi”)
Executive Vice President, Chief Commercial Officer
Nawawi has served as our Executive Vice President, Chief Commercial Officer since October 2025.
Background
Nawawi is a strategic and operational leader with more than 20 years of experience across the U.S., Europe, and the Middle East, spanning global, regional, and country-level roles in oncology commercialization and leadership. He is recognized for building high-performing, purpose-driven teams and driving growth across competitive and rare disease markets. Before joining Geron, Nawawi served as Senior Vice President and U.S. Commercial Head at Stemline Therapeutics, a Menarini group company, where he led the U.S. commercial organization spanning sales, marketing, market access, commercial excellence, and data analytics. During his tenure, he built and scaled the organization from 30 to 165 employees, achieved consecutive topline and bottom-line growth for three years, and successfully launched ORSERDU® in metastatic breast cancer, which was recently recognized as one of the top oncology launches in recent years. He also revitalized ELZONRIS® performance in blastic plasmacytoid dendritic cell neoplasm (BPDCN), achieving the product’s first-ever year-over-year growth.
Previously, Nawawi held several leadership roles at Novartis Oncology, including Oncology General Manager for Romania and the Gulf region, Executive Director for U.S. Melanoma, and Global Indication Lead for both breast and lung cancer. Across these roles, he led cross-functional teams, managed full P&L ownership, launched multiple first-in-class therapies, and shaped global go-to-market strategies for brands such as KISQALI® and capmatinib. Earlier in his career, he held commercial and marketing positions in Egygt, the UAE, and Saudi Arabia with Merck and Schering-Plough. He holds an MBA from the University of Leicester and a B.S. in Clinical Pharmacy from Ain Shams University in Cairo, Egypt.